Drug Management of Prostate Cancer
This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe st
- PDF / 8,954,495 Bytes
- 421 Pages / 547.087 x 737.008 pts Page_size
- 99 Downloads / 248 Views
William D. Figg · Cindy H. Chau · Eric J. Small Editors
Drug Management of Prostate Cancer
Editors William D. Figg National Cancer Institute Bethesda, MD USA
Eric J. Small University of California, San Francisco San Francisco, CA USA
Cindy H. Chau National Cancer Institute Bethesda, MD USA
ISBN 978-1-60327-831-7 e-ISBN 978-1-60327-829-4 DOI 10.1007/978-1-60327-829-4 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010936435 © Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Preface
Prostate cancer is the most common noncutaneous malignancy and the second leading cause of cancer deaths among men in the United States. It is a critical public health problem and remains incurable in the metastatic setting with mortality that usually occurs as a result of castration-resistant disease. Since Huggins and Hodges’ report of the dramatic clinical effects of suppressing serum testosterone levels in men with advanced prostate cancer in 1941, hormone therapy (also called androgen deprivation therapy [ADT]) has become widely accepted as the mainstay of therapy for the treatment of advanced prostate cancer. ADT combined with radiation therapy is a standard of care in the treatment of men with locally advanced prostate cancer on the basis of evidence that shows improved survival. The role of ADT in the management of prostate cancer is controversial in that it is also used for other prostate cancer states (such as in men with biochemical recurrence after radical prostatectomy or lymph node metastases) even though the clinical effects of hormone therapy in these other settings have not been definitively proven to be beneficial. Hence the first part of this volume will focus on the role of hormone therapy in the management of advanced prostate cancer and address the controversies relevant to the role of ADT, including the time to initiate ADT, optimum duration of ADT, the benefits of combined androgen blockade, the role of intermittent ADT, and the benefits of secondary hormonal therapies. In men whose cancer is no longer responding to hormone therapy, the treatment paradigm is shifted toward chemotherapy and other investigational options. In 2004, two landmark trials using do
Data Loading...
